Icon

PEPCID (nda019462)- (20MG,40MG)

FAMOTIDINE BAUSCH
20MG,40MG
Yes No
2001-Apr-15 Expired
None None
None No
PEPCID is a histamine-2 (H2) receptor antagonist indicated: In adult and pediatric patients 40 kg and greater for the treatment of:  active duodenal ulcer (DU).  active gastric ulcer.  symptomatic nonerosive gastroesophageal reflux disease (GERD).  erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the:  treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).  reduction of the risk of DU recurrence.
16 0 13
Total Other Developers 8
Drugs with Suitability No
20MG ** ** - - 11
40MG ** ** - - 10
NDA Sales Available Total Generic Sales Available
No 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** *** **** ****** ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***
****** ********* ** ********* *****, *** *********** ** *******-**, ******-***, *********-**, ********, **************-** *****, *****, ***** (***) ***
****** ******** ******** **********, ***. *********** **** ******* **, ********, ********** (**) *****, ****** ****** (***) ***
****** ******** ******** **********, ***. *********** **** ********** **, ********, ********** (**) *****, ****** ****** (***) ***
****** ******* ****** *** ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-*, **. **. ***/*, ***/*, ***/*, **** **. *-*/*, ***** ***, ***** ********** ****, ********* (*******), ********* (******), ************ (********), ************, ********* ******, ***** (***) ***
****** ***** **** *** *** ****** ******* ******* *********** ****** **. ** ** **, ******* *******, **********, ****** ******* ******, ***** (***) ***
****** ****** ****** *** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ****** ****** ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ******** ********* ******** ********* ****. *********** *** **** ******, *********, *** **** (**) *****, ****** ****** (***) ***
****** ****** ******* *************** ******* ******* *********** ****** **. ***/* & ***/**, ******* *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** ****** *************** ******* *********** ****, ****** ****, ******, *********, ******* ******, ***** (***) ***
****** ******** ********* ******** ********* ****. *********** *** **** ******, *********, *** **** (**) *****, ****** ****** (***) ***
****** *** *** ************ ******* ******* *********** *********** ********, **** -** **. **'* (***** **) : ***, *** , ***, ***, ***, ***, ***, ***- *** *** *** ******** (*******), ********* (******),, ********** (********), ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.